CClinicalTrials.gg
CompletedNCT03694678Updated May 28, 2025Results posted

Building Resiliency in Patients Admitted to the Neuroscience Intensive Care Unit and Their Caregivers

An interventional study of Recovering Together in Acute Brain Injuries, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The investigators will compare a dyadic intervention (Recovering Together) with an attention placebo educational control in dyads of patients with acute neurological illnesses and their caregivers at risk for chronic emotional distress. The primary aim of this study is to determine the feasibility, credibility, and satisfaction with Recovering Together. The second aim is to show proof of concept for sustained improvement in emotional distress, post traumatic stress (PTS), resiliency and interpersonal communication outcomes in patients and caregivers.

Read the detailed description

The investigators aim to improve the care of patients (pts) admitted to the Neuroscience Intensive Care Unit (NICU) and their family caregivers (cgs) by conducting a pilot feasibility randomized controlled trial (RCT; N=80 dyads; 60 completers) of the dyadic resiliency program ("Recovering Together") to prevent chronic emotional distress in both pts and their cgs. Eligible dyads include adult, English speaking pts with acute neurological injury (ANI) admitted to the NICU, cleared medically and cognitively for participation by the nursing team, and their primary cgs. Dyads who are randomly assigned to "Recovering Together" will receive 6 manualized sessions (2 in person at hospitalization and 4 through live video after discharge, to reduce burden and facilitate access to care) led by a clinical psychologist. Dyads who are randomly assigned to the attention placebo educational control condition will receive 6 manualized sessions (2 in person and 4 through live video with a clinical psychologist), modeled after the Recovering Together program that will control for the dose of the intervention and support from therapist. Dyads will complete assessment surveys before, after the intervention and 3 months later. Clinical data on demographics, diagnosis, ANI severity, and any medical complications will be extracted from electronic health records.

02

Conditions studied

  • Acute Brain Injuries

Browse trials for

Keywords

  • Psychiatry
  • Dyads
  • Patients
  • Caregivers
  • Psychosocial
03

In context

Brain Injuries

2,113 studies on the registry are indexed under Brain Injuries; 385 are open to participants now.

This study's enrollment of 126 is above the median of 48 across 1,331 interventional studies indexed under Brain Injuries.

Browse Brain Injuries studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,536 studies on the registry; 446 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 161 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male and female patients, 18 years or older
  • English fluency and literacy
  • Access to high speed internet for video sessions
  • Patient with an informal cg (family or friend who provides unpaid care) available and willing to participate
  • Hospitalized with an acute brain injury within 1-2 days when first approached, OR the primary caregiver of a patient currently admitted with an acute brain injury
  • Either patient or caregiver within the dyads screens in for depression, anxiety, and/or PTSD

Exclusion criteria

Exclusion Criteria:

  • Permanent or severe cognitive impairment severe enough to impede participation - This will be determined by nurses through an assessment conducted as part of usual care (MMSE).
  • Dyads where the patient is anticipated to die or to never be able to participate due to medical sequelae.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Recovering Together

    Dyads who are randomly assigned to the Recovering Together program will receive any usual clinic care as determined by their clinicians. Additionally, dyads will be invited to participate in 6 30-minute skills sessions. All sessions will include both pt and cg. A clinical psychologist will deliver the majority of sessions while the PI will deliver at least 10% of the sessions. The main intervention goal is to provide dyads with resiliency and interpersonal communication skills necessary to optimize their recovery and reduce emotional distress and PTS.

    Behavioral: Recovering Together

  • No intervention
    Health Education

    Patients randomly assigned to the control condition will receive an educational program that mimics the dose and duration of the Recovering Together Program but without teaching any of the resiliency or interpersonal communication skills that are hypothesized to be responsible for improvement in emotional distress. The control will entail 2 in-person dyadic visits in the NICU and 4 dyadic virtual visits after discharge.

Interventions

  • BehavioralRecovering Together

    The intervention will teach resiliency skills (mindfulness, coping, interpersonal communication, etc) within 2 in person sessions at hospitalization and 4 live video sessions after discharge. Both patient and caregiver will participate in all sessions

06

What researchers measure

Primary outcomes

  1. Feasibility of Recruitment (Ability to Recruit Dyads)

    Feasibility of recruitment will be determined by reporting number of dyads who meet study criteria who enrolled

    Time frame: Baseline

  2. Feasibility of Intervention Delivery (Ability to Deliver Intervention to Dyads)

    We will report number of sessions completed by each dyad. We will report any technical difficulties with live video delivery

    Time frame: Feasibility of program delivery will be measured at 6 weeks

  3. Credibility and Expectancy Questionnaire

    This measure will assess participants' belief that the intervention (or control) will be helpful. The score range is 3-27. Higher scores mean higher perception of credibility or expectancy.

    Time frame: Baseline

  4. Client Satisfaction Questionnaire

    This measure will assess participants' satisfaction with participation in the study. The score range is 0-12. Higher scores indicate greater satisfaction.

    Time frame: post intervention (6 weeks after baseline)

Secondary outcomes

  1. Hospital Anxiety and Depression Scale

    Measures symptoms of emotional distress and estimates diagnoses. The scale has 14 items, 7 assess anxiety and 7 depression. Scores range from 0-21 on each subscale, wtih higher scores indicating more symptoms. Scores greater than 8 indicate clinically significant symptoms.

    Time frame: baseline to posttest to 3 months follow up

  2. Post Traumatic Checklist

    The PTSD CheckList - Civilian Version measures symptoms of post traumatic stress and determines diagnoses. Scores range from 17-85. Higher scores indicate more severe stress.

    Time frame: baseline to posttest to 3 months follow up

  3. Measures of Coping Style Part A

    The MOCS-A measures various coping strategies such as relaxation or adaptive thinking. Scores range from 0 to 52, and higher scores indicate greater self-perceived proficiency with these skills.

    Time frame: baseline to posttest to 3 months follow up

  4. Cognitive and Affective Mindfulness Scale Revised

    Measures mindfulness skills used in daily life. The scale ranges from 12 to 48 with higher scores indicating higher mindfulness.

    Time frame: baseline to post test to 3 months follow up

  5. Dyadic Relationship Scale

    The Dyadic Relationship Scale (DRS) has 2 sub scales that assess dyadic strains and dyadic positive interaction. Scales on each sub scale range from 1 to 4, with higher scores indicating great severity of the relevant construct.

    Time frame: Baseline, post treatment, 3-month follow-up

07

Results

Posted May 28, 2025

Participant flow

Participant flow — Overall Study
MilestoneRecovering TogetherHealth Education
Started6062
Patient3031
Caregiver3031
Completed5659
Not completed43
Withdrew: Withdrawal by subject20
Withdrew: Lost to follow-up23

Outcome measures

PrimaryFeasibility of Recruitment (Ability to Recruit Dyads)

Feasibility of recruitment will be determined by reporting number of dyads who meet study criteria who enrolled

Time frame:
Baseline
Reported as:
Count of participants · Participants
Feasibility of Recruitment (Ability to Recruit Dyads)
ParticipantsEligible Participants
Participants who enrolled and randomized122
Participants who declined40
Participants who enrolled and did not randomize4
PrimaryFeasibility of Intervention Delivery (Ability to Deliver Intervention to Dyads)

We will report number of sessions completed by each dyad. We will report any technical difficulties with live video delivery

Time frame:
Feasibility of program delivery will be measured at 6 weeks
Reported as:
Number · dyads
Feasibility of Intervention Delivery (Ability to Deliver Intervention to Dyads)
dyadsRecovering TogetherHealth Education
Number of dyads who started RT who had at least 1 member complete post treatment assessment2931
Number of dyads who started RT who had neither member complete post treatment assessment10
PrimaryCredibility and Expectancy Questionnaire

This measure will assess participants' belief that the intervention (or control) will be helpful. The score range is 3-27. Higher scores mean higher perception of credibility or expectancy.

Time frame:
Baseline
Reported as:
Mean · score on a scale
Credibility and Expectancy Questionnaire
score on a scaleRecovering TogetherHealth Education
Credibility and Expectancy Questionnaire; credibility subscale22.0 ± 4.420.3 ± 4.8
Credibility and Expectancy Questionnaire; expectancy subscale19.0 ± 5.219.5 ± 5.6
PrimaryClient Satisfaction Questionnaire

This measure will assess participants' satisfaction with participation in the study. The score range is 0-12. Higher scores indicate greater satisfaction.

Time frame:
post intervention (6 weeks after baseline)
Reported as:
Mean · score on a scale
Client Satisfaction Questionnaire
score on a scaleRecovering TogetherHealth Education
Client Satisfaction Questionnaire10.65 ± 1.189.87 ± 2.70
SecondaryHospital Anxiety and Depression Scale

Measures symptoms of emotional distress and estimates diagnoses. The scale has 14 items, 7 assess anxiety and 7 depression. Scores range from 0-21 on each subscale, wtih higher scores indicating more symptoms. Scores greater than 8 indicate clinically significant symptoms.

Time frame:
baseline to posttest to 3 months follow up
Reported as:
Mean · score on a scale
Hospital Anxiety and Depression Scale
score on a scaleRecovering Together: PatientsRecovering Together: CaregiversHealth Education: PatientsHealth Education: Caregivers
Baseline: depression8.7 ± 4.27.8 ± 2.77.1 ± 4.04.8 ± 3.8
Posttreatment: depression4.0 ± 4.13.28 ± 3.377.2 ± 3.76.1 ± 5.4
3-month follow-up: depression3.7 ± 3.32.42 ± 2.587.7 ± 5.07.27 ± 5.28
Baseline: anxiety11.1 ± 4.713.2 ± 3.96.3 ± 4.07.0 ± 4.7
Posttreatment: anxiety3.3 ± 4.16.0 ± 3.88.5 ± 5.28.1 ± 6.1
3-month follow-up: anxiety4.7 ± 4.85.3 ± 3.88.9 ± 6.09.62 ± 5.02
SecondaryPost Traumatic Checklist

The PTSD CheckList - Civilian Version measures symptoms of post traumatic stress and determines diagnoses. Scores range from 17-85. Higher scores indicate more severe stress.

Time frame:
baseline to posttest to 3 months follow up
Reported as:
Mean · score on a scale
Post Traumatic Checklist
score on a scaleRecovering Together: PatientsRecovering Together: CaregiversHealth Education: PatientsHealth Education: Caregivers
Baseline41.6 ± 12.943.2 ± 10.729.3 ± 12.129.4 ± 12.0
Posttreatment26.4 ± 10.839.3 ± 9.834.6 ± 12.135.9 ± 16.6
3-month follow-up28.2 ± 10.127.3 ± 7.741.7 ± 16.037.7 ± 16.1
SecondaryMeasures of Coping Style Part A

The MOCS-A measures various coping strategies such as relaxation or adaptive thinking. Scores range from 0 to 52, and higher scores indicate greater self-perceived proficiency with these skills.

Time frame:
baseline to posttest to 3 months follow up
Reported as:
Mean · score on a scale
Measures of Coping Style Part A
score on a scaleRecovering Together: PatientsRecovering Together: CaregiversHealth Education: PatientsHealth Education: Caregivers
Baseline2.2 ± .82.3 ± .62.6 ± .92.5 ± .9
Posttest2.7 ± .82.6 ± 1.12.4 ± .82.4 ± 1.2
3-month follow-up2.5 ± .72.5 ± .92.2 ± 1.02.3 ± 1.0
SecondaryCognitive and Affective Mindfulness Scale Revised

Measures mindfulness skills used in daily life. The scale ranges from 12 to 48 with higher scores indicating higher mindfulness.

Time frame:
baseline to post test to 3 months follow up
Reported as:
Mean · score on a scale
Cognitive and Affective Mindfulness Scale Revised
score on a scaleRecovering Together: PatientsRecovering Together: CaregiversHealth Education: PatientsHealth Education: Caregivers
Baseline34.2 ± 7.034.6 ± 5.835.1 ± 7.836.4 ± 7.6
Posttreatment36.7 ± 7.736.3 ± 6.535.0 ± 10.736.7 ± 8.5
3-month follow-up35.5 ± 7.936.3 ± 7.532.3 ± 9.033.3 ± 9.4
SecondaryDyadic Relationship Scale

The Dyadic Relationship Scale (DRS) has 2 sub scales that assess dyadic strains and dyadic positive interaction. Scales on each sub scale range from 1 to 4, with higher scores indicating great severity of the relevant construct.

Time frame:
Baseline, post treatment, 3-month follow-up
Reported as:
Mean · score on a scale
Dyadic Relationship Scale
score on a scaleRecovering Together: PatientsRecovering Together: CaregiversHealth Education: PatientsHealth Education: Caregivers
Dyadic strain: baseline2.0 ± .82.0 ± .72.0 ± .781.8 ± .7
Dyadic strain: posttreatment1.6 ± .62.01 ± .82.0 ± .92.1 ± .9
Dyadic strain: 3-month follow-up1.9 ± .82.2 ± .82.0 ± .92.2 ± .8
Positive interactions: baseline3.1 ± .53.0 ± .53.2 ± .63.3 ± .4
Positive interactions: posttreatment3.4 ± .63.3 ± .52.97 ± .773.2 ± .7
Positive interactions: 3-month follow-up3.2 ± .63.2 ± .62.82 ± .673.0 ± .7

Adverse events

Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Recovering Together: Patients0/30 (0%)0/30 (0%)0/30 (0%)
Recovering Together: Caregivers0/30 (0%)0/30 (0%)0/30 (0%)
Health Education: Patients0/31 (0%)0/31 (0%)0/31 (0%)
Health Education: Caregivers0/31 (0%)0/31 (0%)0/31 (0%)

Baseline characteristics

Total number of participants (patients and caregivers) who completed \>=1 intervention or control session were analyzed and included in baseline population.

Age, Continuous
Age, Continuous(Years)Recovering Together: PatientsRecovering Together: CaregiversHealth Education: PatientsHealth Education: CaregiversTotal
Mean49.3 ± 16.752.4 ± 14.350.1 ± 16.452.1 ± 14.950.9 ± 15.5
Sex: Female, Male
Sex: Female, Male(Participants)Recovering Together: PatientsRecovering Together: CaregiversHealth Education: PatientsHealth Education: CaregiversTotal
Female922121760
Male207171256
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Recovering Together: PatientsRecovering Together: CaregiversHealth Education: PatientsHealth Education: CaregiversTotal
American Indian or Alaska Native00000
Asian10113
Native Hawaiian or Other Pacific Islander00000
Black or African American242311
White2525242094
More than one race10113
Unknown or Not Reported00145
Employment status
Employment status(Participants)Recovering Together: PatientsRecovering Together: CaregiversHealth Education: PatientsHealth Education: CaregiversTotal
Employed full-time1814121862
Retired568423
Employed part-time13127
Homemaker02125
Full-time or part-time student11114
Other436215
08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Publications

  • Bannon SM, Cornelius T, Gates MV, Lester E, Mace RA, Popok P, Macklin EA, Rosand J, Vranceanu AM. Emotional distress in neuro-ICU survivor-caregiver dyads: The recovering together randomized clinical trial. Health Psychol. 2022 Apr;41(4):268-277. doi: 10.1037/hea0001102. Epub 2021 Sep 9. PubMed 34498896 ↗
  • Vranceanu AM, Bannon S, Mace R, Lester E, Meyers E, Gates M, Popok P, Lin A, Salgueiro D, Tehan T, Macklin E, Rosand J. Feasibility and Efficacy of a Resiliency Intervention for the Prevention of Chronic Emotional Distress Among Survivor-Caregiver Dyads Admitted to the Neuroscience Intensive Care Unit: A Randomized Clinical Trial. JAMA Netw Open. 2020 Oct 1;3(10):e2020807. doi: 10.1001/jamanetworkopen.2020.20807. PubMed 33052404 ↗

Study documents

  • Protocol and statistical analysis plan · Aug 6, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03694678
Lead sponsor
Massachusetts General Hospital
Responsible party
Ana-Maria Vranceanu, PhD (Director of Integrated Brain Health Clinical and Research Program, Massachusetts General Hospital) — Principal investigator
First posted
Oct 3, 2018
Start date
Jan 1, 2019
Primary completion
Oct 1, 2020
Completion
Oct 11, 2020
Results posted
May 28, 2025
Last update
May 28, 2025

Study contacts

Ana-Maria Vranceanu, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion